Abstract:Background: Aquaporin 4-immunoglobulin G (AQP4-IgG) plays a major role in the pathogenesis of neuromyelitis optica spectrum disorder (NMOSD). Seropositive status for this antibody has become one of the required indicators for NMOSD diagnosis.Objective: Our goal was to systematically review and perform a meta-analysis of the current works of literature evaluating the clinical relevance of serum AQP4-IgG titer in patients with NMOSD. We sought to determine whether AQP4-IgG could indicate disease activity or severity, in addition to its diagnostic value in NMOSD.Methods: Electronic databases were searched for published literature, yielding 4,402 hits. Of the 124 full articles screened, 17 were included in the qualitative analysis and 14 in the meta-analysis.Results: There were no significant differences in serum AQP4-IgG titers between the relapse and remission phases in patients with NMOSD [standard mean difference (SMD): 0.32, 95% CI (−0.10, 0.74), p = 0.14]. Subgroup meta-analysis of AQP4-IgG detected by cell-based assays (CBA), an AQP4-IgG testing method recommended by the 2015 international consensus diagnostic criteria for NMOSD, confirmed the aforementioned result [SMD: 0.27, 95% CI (−0.01, 0.55), p = 0.06]. Moreover, the serum AQP4-IgG titer was positively correlated with the number of involved spinal cord segments [correlation coefficient (COR): 0.70, 95% CI (0.28–0.89), p = 0.003] and the Expanded Disability Status Scale (EDSS) score [COR: 0.54, 95% CI (0.06-0.82), p = 0.03] in the attack phase in patients with NMOSD.Conclusions: The present study systematically assessed the association between serum AQP4-IgG titer and NMOSD activity and severity. The results demonstrated that the serum AQP4-IgG titer was not associated with disease activity but indicated the disease severity in the attack phase in patients with NMOSD. A further meta-analysis with a larger number of studies that employed standardized AQP4-IgG assays and detected attack–remission paired samples from the same patients with detailed medication information will be required to confirm our findings and shed more light on optimizing clinical AQP4-IgG monitoring.Systematic Review Registration: [www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=208209], PROSPERO, identifier [CRD42020208209].

Different Exosomal Microrna Profile in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders.

Identification of a Distinct Exosomal Microrna Profile in Neuromyelitis Optica Spectrum Disorders by Next-generation Sequencing

Serum Aquaporin 4-Immunoglobulin G Titer and Neuromyelitis Optica Spectrum Disorder Activity and Severity: A Systematic Review and Meta-Analysis

Serum Molecular Biomarkers in Neuromyelitis Optica and Multiple Sclerosis.

Astrocyte-Derived Exosomes Contribute to Pathologies of Neuromyelitis Optica Spectrum Disorder in Rodent Model

Astrocyteâ€�derived exosomes contribute to pathologies of NMOSD in rodent model

Cytokine and Chemokine Profiles in Patients with Neuromyelitis Optica Spectrum Disorder.

Immune Repertoire Profiling Reveals Its Clinical Application Potential and Triggers for Neuromyelitis Optica Spectrum Disorders

Identification of potential biomarkers for neuromyelitis optica by quantitative proteomics

Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity.

Non-target metabolomics profiling of neuromyelitis optica spectrum disorder.

Autoantibody to MOG Suggests Two Distinct Clinical Subtypes of NMOSD

Whole‐exome Sequencing Reveals the Major Genetic Factors Contributing to Neuromyelitis Optica Spectrum Disorder in Chinese Patients with Aquaporin 4‐igg Seropositivity

Serum Molecular Biomarkers in Neuromyelitis Optical and Multiple Sclerosis

Association of plasma sPD‐1 and sPD‐L1 with disease status and future relapse in AQP4‐IgG (+) NMOSD

Analysis of AQP4/NMO-IgG Antibody Positive Patients with Neuromyelitis Optica Spectrum Disorders

Imaging Transcriptomics of Brain Functional Alterations in MS and Neuromyelitis Optica Spectrum Disorder

The Role of Gut Microbiota in Neuromyelitis Optica Spectrum Disorder

Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder

Comparison of Clinical Characteristics and Prognoses in Patients with Different AQP4-Ab and MOG-Ab Serostatus with Neuromyelitis Optica Spectrum Disorders